GO
Loading...

Novartis AG

More

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • *Barclays recommendation upgrade lifts Novartis. PARIS, June 10- European stocks inched up on Tuesday, extending a three-week rally, led by gains in defensive Swiss blue-chips such as pharma group Novartis, boosted by an upbeat broker note.

  • *Gemalto boosted by Chinese contract. PARIS, June 10- European equities climbed to new peaks on Tuesday, with Germany's DAX stock market setting a new record high.

  • Why these 3 biotech stocks are making big moves Monday, 2 Jun 2014 | 9:44 AM ET

    Thousands of oncologists, investors, researchers and analysts descended on Chicago for the annual ASCO, the year's biggest cancer research meeting.

  • Early movers: BRCM, MYL, GOOG, Z & more Monday, 2 Jun 2014 | 7:37 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • CHICAGO, May 31- Cancer doctors should consider the financial as well as the medical impact of treatment for patients as healthcare costs continue to grow faster than the overall economy, according to experts in Chicago at the annual meeting of the world's largest organization of oncologists.

  • NEW YORK, May 29- A federal judge on Thursday refused to dismiss a U.S. government lawsuit accusing Novartis AG of civil fraud for having conducted two illegal kickback schemes to boost sales of drugs covered by Medicare and Medicaid.

  • NEW YORK, May 29- A federal judge has refused to dismiss a U.S. government lawsuit accusing Novartis AG of civil fraud for having conducted two illegal kickback schemes to boost sales of drugs covered by Medicare and Medicaid.

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • GSK invites private equity bid for drugs: Sources Thursday, 29 May 2014 | 12:34 PM ET
    A GlaxoSmithKline Plc logo sits on a sign outside the company's headquarters in London, U.K.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • Immuno-what? How these cancer therapies work Thursday, 29 May 2014 | 12:27 PM ET

    A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • GSK invites private equity bids for older drugs -sources Thursday, 29 May 2014 | 11:09 AM ET

    LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, according to two people with direct knowledge of the matter. The move is part of a reshaping of the drugmaker's business, which also involves a major asset swap deal with Novartis.

  • Why Pfizer should try to buy Bristol-Myers Tuesday, 27 May 2014 | 1:21 PM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    What's next for Pfizer, now that its bid for AstraZeneca has been laid to rest, at least temporarily. Analysts weigh in with their views.

  • Chinese city targets pharma firms in graft crackdown Tuesday, 27 May 2014 | 9:08 AM ET

    SHANGHAI, May 27- China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

  • LONDON/ NEW YORK, May 26- Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds on Monday as a deadline approached without a last-minute change of heart by the British drugmaker.

  • LONDON/ NEW YORK, May 26- Pfizer said on Monday it had abandoned its current attempt to buy AstraZeneca for nearly 70 billion pounds as a deadline approached without a last-minute change of heart by the British drugmaker. Its decision to quit the stage, at least for now, had been widely expected after AstraZeneca refused its final offer of 55 pounds a share.

  • A bitter pill as China crackdowns squeeze pharma margins Saturday, 24 May 2014 | 10:00 PM ET

    China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by- a concern as many global firms look to China as a future growth driver.